Habib Dable: Thank you, Todd. Good morning, everyone and thanks for joining us today. It's clearly an exciting time at Acceleron with recently provided program updates over the past few weeks and additional updates announced this morning. Based on faster than expected rates of patient requirement in the MEDALIST and BELIEVE Phase 3 studies year-to-date at Celgene. Our luspatercept collaboration partner recently announced that we expect full patient enrollment to be achieved this quarter versus our previous guidance of the second half of 2017. This should now put us in the position to report top line results from the Phase 3 trials by the middle of 2018. We at Celgene also announced that we plan to initiate a new Phase 3 trial with luspatercept and first-line lower risk MDS patient in early 2018. This decision is supported by results presented over the weekend at the MDS Symposium that Matt will be discussing later on this call. For the ACE-083 program, we announced plans to initiate a second Phase 2 trial in neurological disease called Charcot-Marie-Tooth disease, or CMT that causes muscle weakness in specific muscles. We expect this two part Phase 2 study to begin in the middle of this year with the part one dose escalation results available in 2018. Our team recently hosted an educational webinar to discuss the background on CMT and our Phase 2 trial design. We were joined by a leading neuromuscular expert, Dr. David Walk [ph], Associate Professor of Neurology and Director of the ALS and CMC Centers of Excellence at the University of Minnesota Medical Center. A reply of this event is available in the events and presentation section of the investor's media page on our corporate website. While we are working on ACE-083 trial start-up activities in CMT, enrollment and treatment are ongoing in the part one dose escalation stage of our Phase 2 trial in Facioscapulohumeral Muscular Dystrophy or FSHD. I'll now turn the call over to Matthew Sherman, our Chief Medical Officer, to review highlights from our luspatercept two presentations at the MDS from this past weekend.
Habib Dable: Thanks, Geoff. So with the details of the study, I will hand it over to Matt, and then I'll follow up with that in terms of the population in terms of the percentages. 
Habib Dable: And then in terms of weight based dosing question, I think weâ€™re very comfortable with the Pk/Pd modeling that we've done for this protein to show that the efficacy that we're seeing does require weight base dosing, so there's no plan to do flat in the near future must have or so.
Habib Dable: Hi Chris, let me answer the question about them the -- the role of ACE-083 and CMT and make a comparison to FSHD as well too. So these are two neuromuscular diseases that we targeted now for Phase 2 trials to investigate the role of ACE-083, ACE-083 first is a broader acting agent in just a myostat inhibitor; so as we discussed inhibits multiple negative ligands they can regulate muscle growth and functions. But these six diseases are distinct I think there is two pronged approach to the important ones to recognize from an FSH dystrophy there is an impairment in the muscle itself it is a muscle dystrophy. So our expectations to increase muscle strength in that setting, in CMP the muscles impact is just the innovation for the nerve to the muscle that isn't here. So the muscle itself is relatively healthy into undergoes atrophy after no prolonged period of this innovation. So that's setting again increasing the volume, the strength, the function of the existing muscle to help those patients overcome their impairment. We had a webinar a month and a half ago, about the study, I think it's really informative for folks to actually try to listen to some of the details that were preserved by Dr. David Walk [ph] but these are patients were pretty troubled by their -- by their illness the foot drop presenting with a high step gate [ph] leading to trips and falls in these patients, without any therapeutic available for these patients other than just the orthopedic bracing of their -- of their ankle there's quite incoherent in their mobility.  So the ability of FSHD to increase strength I expect will be very significant benefit, for these patients. I guess I should also mention the ongoing pre-clinical [ph] work that we've done as well have supported the role of the ACE-083 to increase muscle function across a wide number of preclinical models and different neurological diseases, so again that adds to the evidence from the potential benefit for the agent in these Phase 2 trials.
Habib Dable: Exactly, so the trials in designing two part trials, there's an open label there somewhere both trials are similar in designing, first an open label part of the trial which has a small dose escalation opponent and in that part we're going to be focusing primarily on muscle volume, the primary activity as we demonstrated on healthy volunteers, and in part two randomized and placebo-controlled and in that setting not only muscle volume will be evaluated, but also muscle strength using fixed stress testing and hands on a monetary testing and a number of functional outcome measures. I think as the as the trials will move along will spend a little more time talking on the important of these outcome measures. These include things such as a six minute walk test you are familiar with that, but also the 10 meter walk run of [indiscernible] test, activity measures of the upper extremities called pull test which is performance of the upper limbs and basically in the CMP population, a test called the burden balance test.  And this is a 14 component test. Looking at patients ability to have -- have a good balance either by standing or sitting on one foot, turning in 360 degrees. So really quite sophisticated testing of their muscle function. Furthermore, both of these studies we're actually looking at that the patient gate, so we are using highly sophisticated gate analyses to measure their ability to -- to improve their emulation. So I think I will excited to see the state as a -- as a young fold [ph] the over the next year. 
Habib Dable: So we are at database analysis now, we've already passed through the late breaker time period for [indiscernible]; so you could expect that would just be a press release from us outlining the top line results. 
Habib Dable: Hi Ed, thanks for the question, so yes that was actually exactly the plan just put into context when we did the first part of the Phase 2 study we had a total of 58 patients from the first part through the first extension cohort. The second extension cohort including RS-negative patients was probably 50 additional patient, 31 of those patients were available for this update at the Symposium meeting. So we anticipate approximately 24 patients that we will have data so -- there will be [indiscernible] obviously for 2017 to include the remaining patients who are enrolled, as well as showing the extension; you know, the durability of activity on these patients as we have done over surplus years for the first cohort of patients.
Habib Dable: Hi Jason, so -- yes, in regard to your first question about EPO level; it's really tends -- it tends to be more of a drop-off, so when we showed the data with various cuts of baseline EPO levels, less than 200 and then the grouping between 200 and 500; you know, there was very little difference in the response rate for the HI-E response; over 63% of less than 200 versus 53% for the 200 to 500 baseline EPO population. Greater than 500 though it did drop down to 27%, so it's that cut-off of 500 that -- less [indiscernible]; you know, we've seen this drop-off inactivity. Yes, Phase really are much more active though in a much lower range there and as we highlighted the Phase 3 trials for Darbepoetin and Epoetin, you know, there the activity is very much limited to baseline EPO levels, less than 100 or perhaps upto 200 but really not even indicative for patients between 200 and 500 grams [ph], so we have -- I think a clear benefit in that patient population. In terms of [indiscernible], you know, there are patients who dropout for various reasons, sometimes -- you know, I don't want to really go into the details where the patients plot [ph] but sometimes it's obviously just due to social reasons for patients participating in the clinical trials, travelling, again these are older populations sort of coming in with a frequency of visits and trying to make that trip. It was I think in Germany, you know, CARE for MDS patients is lot more centralized as many of these patients travelling 50, 60, 100 kilometers to get to their clinic for treatment, so part of that I think, you know, it has an impact on the patients involvement in the trial overtime.
Habib Dable: Yes, thank you, operator. So obviously an awful lot of interest and excitement over the recent data announcement. So I thank you all for your questions and I do look forward to meeting with you at some future investor conferences and medical meetings as we head into December month and wishing you all a great day. Thanks everybody.
Matthew Sherman: Hi Geoffrey, this is Matt. So let me take the second question you're asking, which related to win-win class and the transfusion seen sometimes in patients after they'd have a prolonged period of transfusion dependence. As you know, the average age of onset of MDS patients is that 70 years in our study, the median age was 72 years in patients are often to the Phase 2 trial. So the disease in the elderly many patients have co morbidities. And so if you look out over several years in these patient's history has often-other medical illnesses of problems that arise.  So might be related to a periods of infection for example, when patient might have -- have a bacterial oral affection they're sick they need a boost in transfusions a period of time. More specifically for one of our patients there was a period of GI bleeding, that was unrelated to the drug that occurred to another issue and that requires some transfusions as well. So it is those kinds of events that account for these small bursts of transfusion, we've not seen any drop off of the efficacy of the drug though over time. 
Matthew Sherman: Hi Carter, this is Matt. So yes, right now describing the frontline study because I think really it builds on the excitement that we've seen in this, yes they may be of population, there's -- there is tremendous enthusiasm that came out of the -- the Symposium meeting in Valencia just over last week and this weekend. Highlighting which covers up as one of the leading drug now and phase three development, living into the frontline setting sets us up for going head-to-head to and ESA therapy. The data that we generated ratios with very roust rates we are seeing with patients in baseline EPO levels within 500, which is the majority of patients. ESA-naive population both importantly both are as positive in ours negative patients. The duration of responses although it's still early days, there is not sure that there's a significant difference between those two populations.  So if you move forward with this program, there will be more details forthcoming, those will be able to update folks on the specifics of the status line and collaboration with Celgene now towards later this year as -- as we have the details so to discuss.
Matthew Sherman: Hi Andrew, again this is Matt. So safety profile that this drug actually been very, very well tolerated over the multiple years now that it's been in our many years now been in development. So the small numbers of related great three adverse events that we admitted, have not been anything that we can say specifically related to the mechanism of the drug. Then again the currents of those generally have been very low frequency. 
Matthew Sherman: Yes, I mean that this is again always in the eyes of the investigators understanding of the patient, that generally the temporal relationship of the event to the administration of the drug but it's -- it's and it's much more of an art than a science. And there really requires a randomized control trial to -- to delineate whether or not any of these really have an increased frequency. And treatment population versus the control population. They have to know not -- not reach the level of being a serious adverse event, so they were generally more -- more tolerated by patients.
Matthew Sherman: Yes, certainly given the elderly population they have a number of co morbidities as well too so. Now with cardiovascular disease being a primary issue among these patients could have that active, cardiovascular disease such as the recent MRI but they certainly have had -- many of them have had long standing history so hypertension, atherosclerotic heart disease, [indiscernible]; altogether not a surprise that there would be the currents of other adverse events just over the concourse of patient participation into a multi-year clinical trial. 
Matthew Sherman: Hi Alethia, this is Matt. So for the first question regarding to the lack of response in patients with high baseline EPO level, I think that really does reflect the stage of their disease, those -- those with patients who really bone marrow, almost consider to be burned out marrow, they've been flocked significantly with their own endogenous EPO levels in there -- they've tried to overcome the ineffective erythropoiesis to the point where it's pretty much exhaustion of the marrow. So that setting luspatercept has had limited activity as does ESA and certainly as does any other therapy trying to increase red blood cells. So not necessarily surprised more reflection of the advanced nature of those patients disease.  Regarding the -- accelerated enrollment of -- rapid enrollment of the Phase 3 trial, again I think it really reflects just the building enthusiasm momentum with opportunity for luspatercept patient opportunity, also reflect those other very limited options for these patients. So together that really drove a much more rapid uptake of -- of participation, and recognizing even with the randomized control placebo controlled trial, which sometimes limitations to enrollment many patients obviously recognizing may not want to be on the placebo age but given the lack of opportunities and the excitement building for luspatercept, we were thrilled with -- with the enrollment. 
Matthew Sherman: Hi Mike, so yes, first in regards to your question what I think you're referring to is not a RS-negative patient, RS-negative patient with high EPO level. 
Matthew Sherman: And that context thinking about marrow, I think it is very different situation though in the myelofibrosis, in the myelofibrosis patients their marrows aren't actually highly reactive marrows accounts with the fibrotic nature in -- in their in their marrow. So they as we showed last year you're -- you're quite familiar with the data that we presented with [indiscernible], you know, high degree of erythropoietin response in patients who had really advanced and that that was the investigator initiated trial that was done by surgical for cellstack at MD Anderson. And on that basis, certainly moving ahead to initiate the Phase 2 trial of luspatercept in patients with myelofibrosis, so still I believe there's a high degree of enthusiasm optimism right now to be working with NMF [ph] patience, very distinct disease than MDS.
Matthew Sherman: Again, this is Matt answering the question. So good questions but I don't think I have a lot of information right now to share with you, as we get further along with this specifics of the design for the command study in the first line MDS patient population to be able to talk specifically, my end point would be and the specifics of the patient population, I know people would want to look forward to the specific eligibility criteria that we certainly shown the -- the range of activity we've seen in the lower Phase [ph] level of patience and ESA-Naive population as well too, but I think that that's as far as we can talk about the specifics today, but stay tuned later in this year.  In terms of myelofibrosis, I think it's really similar as we get a little closer, get a little bit more keyed up to be giving a Phase 3 trial, I think together with our partners Celgene will be able to align the -- the eligibility criteria in the specific end point and the study population for the MF study as well too. 
Matthew Sherman: Yes. So I can start to let people know where we are with that study if I can jump in about how the data will be released too, but we did talk about we -- we reached our 82nd PSFGN [ph] as that was prospectively prescribed in the study designed to do the analysis for the top line results, to show the effect of luspatercept combination with exutinib [ph] versus single agent exutinib [ph] plus placebo. We've met a second event and we also completed the enrollment of 130 patients, so just now doing the analysis. And we can talk about that when we have the data presented.
Matthew Sherman: Hi Mike. So they said several of them were just for social reasons for the patients willing to participate in the co-trials such as this and given their age. You know, sometimes it was disease progression; you know, these patients do have progressing unrelated to -- well, they can maintain their anemia but -- I'm sorry, their hematologic response to luspatercept but they can have progression of other underlying MDS. So there is other reasons obviously for these patients coming off study; but this is -- you know, this didn't seem untoward compared to other studies that we've looked at in terms of patients discontinuing.
Matthew Sherman: I mean as a physician who has treated MDS in the past too, I think this kind of activities is fairly impressive activity and I think that was reflected by the enthusiasm that both the investigators from the trial, as well as from the general MBS community appreciate it at the MDS Symposium Conference given the very limited options that these patients have. It was clearly very enthusiastic reception for the data at the meeting in Valencia.
